Recent DOJ and DEA actions have advanced federal marijuana policy following President Trump’s December 2025 executive order directing expedited rescheduling to Schedule III. In April 2026, officials issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28, while withdrawing prior proceedings to streamline the process. An expedited administrative hearing on broader rescheduling of all marijuana from Schedule I begins June 29, 2026, with a compressed timeline ending no later than July 15. These steps reflect administration priorities on research access and regulatory consistency, though full implementation for non-medical cannabis depends on the hearing outcome and any subsequent rulemaking or legal challenges.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$762,399 ปริมาณ
Mar 31, 2026
June 30
2%
December 31
26%
$762,399 ปริมาณ
June 30
$338,633 ปริมาณ
2%
December 31
$158,884 ปริมาณ
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent DOJ and DEA actions have advanced federal marijuana policy following President Trump’s December 2025 executive order directing expedited rescheduling to Schedule III. In April 2026, officials issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28, while withdrawing prior proceedings to streamline the process. An expedited administrative hearing on broader rescheduling of all marijuana from Schedule I begins June 29, 2026, with a compressed timeline ending no later than July 15. These steps reflect administration priorities on research access and regulatory consistency, though full implementation for non-medical cannabis depends on the hearing outcome and any subsequent rulemaking or legal challenges.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$762,399วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent DOJ and DEA actions have advanced federal marijuana policy following President Trump’s December 2025 executive order directing expedited rescheduling to Schedule III. In April 2026, officials issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28, while withdrawing prior proceedings to streamline the process. An expedited administrative hearing on broader rescheduling of all marijuana from Schedule I begins June 29, 2026, with a compressed timeline ending no later than July 15. These steps reflect administration priorities on research access and regulatory consistency, though full implementation for non-medical cannabis depends on the hearing outcome and any subsequent rulemaking or legal challenges.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$762,399วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent DOJ and DEA actions have advanced federal marijuana policy following President Trump’s December 2025 executive order directing expedited rescheduling to Schedule III. In April 2026, officials issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28, while withdrawing prior proceedings to streamline the process. An expedited administrative hearing on broader rescheduling of all marijuana from Schedule I begins June 29, 2026, with a compressed timeline ending no later than July 15. These steps reflect administration priorities on research access and regulatory consistency, though full implementation for non-medical cannabis depends on the hearing outcome and any subsequent rulemaking or legal challenges.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย